___

• Overview ofpsoriasis and guidelines of care for the treat- ment of psoriasis with biologics. J Am Acad Dermatol 58:826-50, 2008
• Singh G, Aneja SP. Cardiovascular comorbiditiy in psoria- sis. Indian J Dermatol 2011 Sep-Oct;56(5):553-6.
• Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM.Prevalence of cardiovascular risk factors in patients with psoriasis. J AmAcad Dermatol 2006; 55: 829–35.
• Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortal- ity in patientswith psoriasis: results from a population- based study. Arch Dermatol 2007; 143: 1493-9.
• Kaye JA, Li L, Jick SS. Incidence of risk factors for myo- cardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
• Makgoba MW, Sanders ME, Shaw S. The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition. Immunol Today 1989; 10: 417-22.
• Das RP, Jain AK, Ramesh V. Current concepts in the patho- genesis of psoriasis. Indian J Dermatol 2009;54:7–12.
• Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64:30–6.
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–95.
• Blauvelt A. New concepts in the pathogenesis and treat- ment of psoriasis: key roles for IL-23, IL-17A anf TGF-β 1. Expert Rev Dermatol 2007;2:69–78.
• Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059–68.
• Ranjbaran H, Sokol SI, Gallo A, et al. An inflammatory pathway of IFN-gamma production in coronary athero- sclerosis. J Immunol 2007;178:592–604.
• Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006: 1: 297–329.
• Hansson GK, Libby P. The immune response in atherosclerosis:a double-edged sword. Nat Rev Immunol 2006: 6:508–19.
• Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart dis- ease in psoriasis. J Am Acad Dermatol 2007: 57: 347–54.
• Stenderup K, Rosada C, Worsaae A, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009: 160: 284–96
• Piérard-franchimont C, Quatresooz P, Piérard GE, Scheen AJ.The psoriasis--metabolic syndrome comorbidity, a complex multigenic disease. Rev Med Liege 2012;67(5- 6):337-40.
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein,the metabolic syndrome, and risk of incident car- diovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003: 107: 391–7.
• Friedewald VE, Cather JC, Gelfand JM, et al. AJC edi- tor’s consensus: psoriasis and coronary artery disease. Am J Cardiol 2008:102:1631–43.
• Guthikonda S, Haynes WG. Homocysteine: role and im- plications in atherosclerosis. Curr Atheroscler Rep 2006: 8:100-6.
• Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009:35:313–24.
• Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006:155:1165–9.
• Tobin AM, Hughes R, Hand EB, Leong T, Graham IM, Kirby B. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clin Exp Dermatol 2011;36(1):19-23.
• Balci DD, Balci A, Karazincir S, Ucar E, Lyigun U, Yalcin F, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009;23:1–6.
• Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a pos- sible risk factor for development of coronary artery calci- fication. Br J Dermatol 2007:156:271–6.
• Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009:218:110–3.
• Soy M, Yildiz M, Sevki Uyanik M, et al. Susceptibility to atherosclerosis in patients with psoriasis and psori- atic arthritis as determined by carotid-femoral (aortic) pulsewave velocity measurement. Rev Esp Cardiol 2009: 62:96–9.
• Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology 2008: 217:27–37.
• Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central china. J Eur Acad Dermatol Venereol 2009;23:1311–5.
• Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-con- trol analysis. Br J Dermatol 2009;160:1048–56.
• Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007;87:506–9.
• Ahmed EF, Seliem MK, El-kamel MF, Abdelgawad MM, Shady I. Prevalence of metabolic syndrome in Egyptian patients with psoriasis. Egypt J Derm and Androl 2009;29:91–100.
• Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012 Jul;89:24-8.
• Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther 2010;23:137–43.
• Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416–22.
• Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabol- ic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010;8:331–4.
• Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2–10.
• Henseler T, Christophers E: Disease concomitance in pso- riasis. J Am Acad Dermatol 1995;32:982-6.
• Gisondi P, Tessari G, Conti A, et al. Prevalence of meta- bolic syndrome in patients with psoriasis: A hospital- based case-control study. Br J Dermatol 157:68-73, 2007
• Al-Rubaiy LK, Al-Rubaiy KK. Alcohol consumption and smoking: A risk factor for psoriasis. Internet J Dermatol 2006;4:2.
• Hamminga EA, van der Lely AJ, Neumann HA, et al. Chronic inflammation in psoriasis and obesity: Implications for therapy. Med Hypotheses 67:768-73, 2006
• Bonifati C, Ameglio F: Cytokines in psoriasis. Int J Dermatol 38:241-51, 1999
• Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus and atherosclero- sis in Israel: A case control study. J Am Acad Dermatol 2007;56:629–34.
• Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: A population-based study. Br J Dermatol 2008;159:1331–7.
• Karadag AS, Yavuz B, Ertugrul DT, et al. Is psoriasis a pre- atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 2010;49(6):642-6.
• Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipo- protein particles and cholesterol efflux capacity in pa- tients with psoriasis. Atherosclerosis 2012;224(1):218-21. Epub 2012 21.
• Pietrzak A, Kadzielewski J, Janowski K, et al. Lipoprotein (a) in patients with psoriasis: Associations with lipid pro- files and disease severity. Int J Dermatol 2009;48:379–87.
• Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic pa- tients. Acta Cardiol 1985;40:199–205.
• Ghiasi M, Nouri M, Abbasi A, Hatami P, Abbasi MA, Nourijelyani K. Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian J Dermatol 2011;56(5):533-6.
• Herron MD, Hinckley M, Hoffman MS, et al. Impact of obe- sity and smoking on psoriasis presentation and manage- ment. Arch Dermatol 2005;141:1527-34.
• Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses’ health study II. Am J Med 120:953-9, 2007
• Fortes C, Mastroeni S, Leffondre K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141:1580-4, 2005
• Orosz Z, Csiszar A, Labinskyy N, et al. Cigarette smoke- induced proinflammatory alterations in the endothelial phenotype: Role of NAD(P)H oxidase activation. Am J Physiol Heart Circ Physiol 292:H130-9,2007
• Farkas A, Kemeny L. Psoriasis and alcohol: Is cutane- ous ethanol one of the missing links? Br J Dermatol 2010;162:711–6.
• Poikolainen K, Reunala T, Karvonen J, et al. Alcohol in- take: A risk factor for psoriasis in young and middle aged men? BMJ 300:780-3,1990
• Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and Alcohol intake in severely affected patiens with pso- riasis in Germany. Dermatology 2010;220:38–43.
• Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA.Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007: 190: 1–9.
• Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006:154: 83–6.
• McDonald I, Connolly M, Tobin AM. A review of psoria- sis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab. 2012;2012:965385. Epub 2012 29.
• Prodanovich S, Prodanowich S,Ma F. Methotrexate reduc- es incidence of vascular diseases in veterans with pso- riasis or rheumatoid arthritis. J Am Acad Dermatol 2005: 52: 262–7.
• Hurlimann D, Forster A, Noll G, et al. Anti-tumor necro- sis factor-alpha treatment improves endothelial func- tion in patients with rheumatoid arthritis. Circulation 2002;106:2184–7.
• Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213–8.
• Fischer LM, Schlienger RG, Matter CM, et al. Discontinuation of nonsteroidal anti-infl ammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004; 164:2472–6.
• Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis:A pilot study. J Am Acad Dermatol 2007;57:529–31.